Qualigen Therapeutics, Inc.

NasdaqCM QLGN

Qualigen Therapeutics, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2024: USD -7.87 M

Qualigen Therapeutics, Inc. Net Income is USD -7.87 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 60.17% change year over year. Net income is the total profit earned by a company after deducting all expenses, including taxes and non-controlling interest.

Qualigen Therapeutics, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -19.76 M, a -7.78% change year over year.
Qualigen Therapeutics, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -18.33 M, a -290.85% change year over year.
Qualigen Therapeutics, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -4.69 M.

Key data

Date	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)	Net Income Margin

NasdaqCM: QLGN

Qualigen Therapeutics, Inc.

CEO	Mr. Kevin A. Richardson II
IPO Date	June 23, 2015
Location	United States
Headquarters	2042 Corte Del Nogal
Employees	4
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

Key trends

Past 5 years